JP2003503042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003503042A5 JP2003503042A5 JP2001506778A JP2001506778A JP2003503042A5 JP 2003503042 A5 JP2003503042 A5 JP 2003503042A5 JP 2001506778 A JP2001506778 A JP 2001506778A JP 2001506778 A JP2001506778 A JP 2001506778A JP 2003503042 A5 JP2003503042 A5 JP 2003503042A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide compound
- twenty
- peptide
- seq
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 239000003145 cytotoxic factor Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR99/08224 | 1999-06-28 | ||
| FR9908224A FR2795415B1 (fr) | 1999-06-28 | 1999-06-28 | Compose peptidique derive d'une orf decalee du gene ice |
| PCT/FR2000/001791 WO2001000784A2 (fr) | 1999-06-28 | 2000-06-27 | COMPOSE PEPTIDIQUE DERIVE D'UNE ORF DECALEE DU GENE iCE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003503042A JP2003503042A (ja) | 2003-01-28 |
| JP2003503042A5 true JP2003503042A5 (https=) | 2008-04-03 |
Family
ID=9547371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001506778A Pending JP2003503042A (ja) | 1999-06-28 | 2000-06-27 | ｉＣＥ遺伝子のシフトされたＯＲＦ由来のペプチド化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6875844B1 (https=) |
| EP (1) | EP1192179B1 (https=) |
| JP (1) | JP2003503042A (https=) |
| AT (1) | ATE309265T1 (https=) |
| AU (1) | AU5992500A (https=) |
| CA (1) | CA2377433A1 (https=) |
| DE (1) | DE60023891T2 (https=) |
| FR (1) | FR2795415B1 (https=) |
| WO (1) | WO2001000784A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
| US7597894B2 (en) | 2003-03-05 | 2009-10-06 | Dendreon Corporation | Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CN104630149B (zh) * | 2013-11-08 | 2018-08-21 | 中国科学院广州生物医药与健康研究院 | 外源线粒体导入到哺乳动物细胞中的方法 |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| WO2018035311A1 (en) * | 2016-08-19 | 2018-02-22 | Gray John T | Compositions and methods for modulating gene expression using reading frame surveillance |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000505650A (ja) * | 1996-02-08 | 2000-05-16 | アメリカ合衆国 | 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物 |
| AU7724398A (en) * | 1997-06-06 | 1998-12-21 | Regents Of The University Of California, The | A melanoma associated antigen, t cell epitopes thereof and methods of using sa me |
| AU9572098A (en) * | 1997-10-08 | 1999-04-27 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Novel human cancer antigen ny eso-1/cag-3 and gene encoding same |
-
1999
- 1999-06-28 FR FR9908224A patent/FR2795415B1/fr not_active Expired - Fee Related
-
2000
- 2000-06-27 AT AT00946023T patent/ATE309265T1/de not_active IP Right Cessation
- 2000-06-27 EP EP00946023A patent/EP1192179B1/fr not_active Expired - Lifetime
- 2000-06-27 US US10/019,219 patent/US6875844B1/en not_active Expired - Fee Related
- 2000-06-27 WO PCT/FR2000/001791 patent/WO2001000784A2/fr not_active Ceased
- 2000-06-27 JP JP2001506778A patent/JP2003503042A/ja active Pending
- 2000-06-27 AU AU59925/00A patent/AU5992500A/en not_active Abandoned
- 2000-06-27 DE DE60023891T patent/DE60023891T2/de not_active Expired - Fee Related
- 2000-06-27 CA CA002377433A patent/CA2377433A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5635399B2 (ja) | 乳癌再発の予防のためのワクチン | |
| BR112019018312A2 (pt) | Plataforma de identificação de peptídeos imunogênicos personalizada | |
| JP2019506843A5 (https=) | ||
| RU2680717C2 (ru) | Олигопептиды металлопротеиназ и их терапевтическое применение | |
| EP2839291B1 (en) | Multivalent breast cancer vaccine | |
| RU2113224C1 (ru) | Продукт полипептидной природы, способ его получения и фармацевтическая композиция, обладающая противоопухолевой и анальгезирующей активностью | |
| US20220267770A1 (en) | Compositions and methods of using c/ebp alpha sarna | |
| EP3480212B1 (en) | Il13ralpha2 peptide and its uses | |
| JP2003503042A5 (https=) | ||
| PT2168594E (pt) | Tratamento de neoplasmas com neurotoxina | |
| JPS62289524A (ja) | ヒトの神経外胚葉性悪性腫瘍と上皮性ガンの治療法 | |
| WO1998015282A1 (en) | Immunogenic tlp composition | |
| CN116655804A (zh) | 一种用于激活嵌合抗原受体效应细胞的中间模块分子及其应用 | |
| Kilmer et al. | Eruptive seborrheic keratoses in a young woman with acromegaly | |
| Singer et al. | Arsenic trioxide reduces 2, 4, 6-trinitrobenzene sulfonic acid-induced murine colitis via nuclear factor-κB down-regulation and caspase-3 activation | |
| CN110075123B (zh) | 一种血液制品及其组合物在制备治疗及预防肿瘤的药物中的用途 | |
| KR101477928B1 (ko) | 암 치료를 위한 pH 민감성 나노운반체 및 그의 제조방법 | |
| TW200303755A (en) | Functional derivatives of the long pentraxin PTX3 for the preparation of an autologous vaccine for the treatment of tumours | |
| CN110305209B (zh) | 用于治疗恶性肿瘤的多肽及其作为疫苗的用途 | |
| AU2003248792B2 (en) | Method of up-regulating tumor antigen expression using thymalfasin | |
| Strassmann et al. | Inhibition of immune reactions in vivo by liposome associated transforming growth factor (TGF) type β1 | |
| JPH0235725B2 (https=) | ||
| Ruan et al. | Roles of Helicobacter pylori in the Epithelial-Mesenchymal Transition of Gastric Cancer | |
| CN120965850A (zh) | 广谱肿瘤多肽疫苗及其应用 | |
| KR20230051139A (ko) | 산화된 면역글로불린을 유효성분으로 포함하는 면역조절 기능 이상 관련 질환 예방 또는 치료용 약학적 조성물 |